Home » Stocks » BNTC

Benitec Biopharma Inc. (BNTC)

Stock Price: $2.77 USD -0.03 (-1.07%)
Updated December 4, 4:00 PM EST - Market closed
After-hours: $2.81 +0.04 (1.44%) Dec 4, 6:15 PM

BNTC Stock Price Chart

Key Info

Market Cap 12.20M
Revenue (ttm) 124,000
Net Income (ttm) n/a
Shares Out 1.11M
EPS (ttm) -9.09
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a

Stock Quote

Trading Day December 4
Last Price $2.77
Previous Close $2.80
Change ($) -0.03
Change (%) -1.07%
Day's Open 2.80
Day's Range 2.75 - 2.82
Day's Volume 103,864
52-Week Range 2.61 - 14.17

BNTC Stock News

PRNewsWire - 1 month ago

HAYWARD, Calif., Oct. 6, 2020 /PRNewswire/ -- Benitec Biopharma Inc. (NASDAQ: BNTC) ("Benitec" or "the Company"), a development-stage, gene therapy-focused, biotechnology company developing no...

PRNewsWire - 2 months ago

HAYWARD, Calif., Oct. 2, 2020 /PRNewswire/ -- Benitec Biopharma Inc. (NASDAQ: BNTC) ("Benitec" or "the Company"), a development-stage, gene therapy-focused, biotechnology company developing no...

PRNewsWire - 2 months ago

HAYWARD, Calif., Sept. 23, 2020 /PRNewswire/ -- Benitec Biopharma Inc. (NASDAQ: BNTC) ("Benitec" or "the Company"), a development-stage, gene therapy-focused, biotechnology company developing ...

PRNewsWire - 3 months ago

HAYWARD, Calif., Sept. 1, 2020 /PRNewswire/ -- Benitec Biopharma, Inc.

PRNewsWire - 4 months ago

HAYWARD, Calif., July 8, 2020 /PRNewswire/ -- Benitec Biopharma, Inc. (NASDAQ: BNTC), a development-stage, gene therapy-focused, biotechnology company developing novel genetic medicines based ...

Investopedia - 9 months ago

Penny stocks can be dangerous, particularly in this economic environment – so quick thinking and stop losses will be your best friends.

Other stocks mentioned: SUPV, TRIB

About BNTC

Benitec Biopharma, a development-stage biotechnology company, focuses on the development of novel genetic medicines. The company develops DNA-directed RNA interference based therapeutics for chronic and life-threatening human conditions. It is developing BB-301, an adeno-associated virus based gene therapy agent for treating oculopharyngeal muscular dystrophy and chronic hepatitis B virus infection. The company was founded in 1995 and is headquartered in Hayward, California.... Full company profile.

Industry
Biotechnology
Founded
1995
CEO
Dr. Jerel A. Banks Ph.D., M.D.
Employees
14
Stock Exchange
NASDAQ
Ticker Symbol
BNTC
Full Company Profile

Financial Performance

Financial numbers in millions AUD.
Financial Statements